Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
240 participants
INTERVENTIONAL
2012-10-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study hypothesis: Pergoveris (LH supplementation) is better than follitropin alpha (non-LH supplementation) for ovarian stimulation in aged IVF patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Based on the difference of 19.1% in the clinical pregnancy rate between the two treatment groups, with and without LH supplementation, in a previous study, with 90% power and a 2-sided P-value of 0.05, the number of subjects required was 109 per group (total 218). The recruitment target was 120 subjects per group (total 240) to allow for dropouts.
Eligible subjects were randomized in blocks of 4 via a computer generated random number list to either the Pergoveris arm or the follitropin alpha arm.
Ovarian stimulation was performed by using GnRH antagonist protocol.
Follitropin alfa (recombinant FSH) was administered on day 2 or day 3 of the menstrual cycle. The first FSH dose was determined according to each individual patient, based on the process as follows:
* AFC ≤ 6: 300 IU/day
* AFC 7-15: 225 IU/day
* AFC ≥ 16: 150 IU/day
GnRH antagonist (Cetrotide, Merck-Serono) was administered on day 5 of FSH administration.
* Recombinant LH (in the form of Pergoveris) was supplemented from day 6 of FSH administration. Patients in the Pergoveris group would be administered a reduced dose of recombinant FSH (reduced by 150 IU/day) which was replaced with Pergoveris (150IU FSH + 75IU LH)/day.
* The Follitropin alpha group retained recombinant FSH. In both groups, if the number of developing follicles was inappropriate, the dose could be titrated depending on the physician's judgment.
Monitoring the follicular development was performed by vaginal ultrasound probe, quantifying LH, estradiol and progesterone, starting from day 5 of FSH, based on the current processes of the hospital.
OPU and embryo transfer: OPU was performed 36 hours after hCG administration. Embryos were transferred on day 2.
Luteal phase support: daily vaginal progesterone
Pregnancy testing and ultrasound: a pregnancy test was done 14 days after embryo transfer. Beta hCG \> 5mIU/ml was considered positive. Fetal ultrasound was performed 3 weeks after a positive pregnancy test to verify clinical pregnancy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pergoveris (FSH and LH)
150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection
Pergoveris (FSH and LH)
Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Follitropin alpha (FSH)
150 IU of recombinant FSH (follitropin alpha or Gonal-F) daily subcutaneous injection
Follitropin alpha (FSH)
Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pergoveris (FSH and LH)
Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Follitropin alpha (FSH)
Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* body mass index \<28 kg/m2
* had ≤ 3 previous IVF attempts
* receiving a GnRH-antagonist protocol
* agreement to participate in the study, and to disclose any medical events to the investigator. The subject must be willing and able to comply with the protocol requirements for the duration of the study.
* have given written informed consent with the understanding that the subject may withdraw consent at any time
Exclusion Criteria
* PCOS or WHO group 1
* have uterine abnormalities
* have endocrine disorders such as hyperprolactinemia, thyroid disorders
35 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vietnam National University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Manh Tuong Ho
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tuong M Ho, MD
Role: PRINCIPAL_INVESTIGATOR
CGRH, School of Medicine, Vietnam National University HCMC, Vietnam
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
An Sinh Hospital
Ho Chi Minh City, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vuong TN, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged >/=35 years: a randomized controlled trial. Hum Reprod. 2015 May;30(5):1188-95. doi: 10.1093/humrep/dev038. Epub 2015 Mar 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCKH/CGRH_01_2012
Identifier Type: -
Identifier Source: org_study_id